Taken together, our data suggest that lung cancer cells use Cav-2 expressed in bone marrow-derived cell types including TAMs to promote tumor growth via inhibiting the anti-tumor immune response and that Cav-2 could be a potential target for cancer immunotherapy. The gene discussed is CAV2; the disease is cancer.